Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)

被引：0
|
作者：
Borthakur, Gautam M. [1 ]
Cortes, Jorge E. [1 ]
Ravandi, Farhad [1 ]
Garcia-Manero, Guillermo [1 ]
Kadia, Tapan M. [1 ]
Jabbour, Elias [1 ]
Patel, Keyur [2 ]
Issa, Ghayas C. [3 ]
Daver, Naval G. [1 ]
Ohanian, Maro N. [1 ]
Brandt, Mark [1 ]
Kantarjian, Hagop M. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA
[3] Univ Texas Houston, Houston, TX USA
[4] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
290
引用
收藏
页数：4
相关论文
共 20 条
  • [1] Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)
    Borthakur, Gautam M.
    Cortes, Jorge E.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Jabbour, Elias
    Patel, Keyur
    Issa, Ghayas C.
    Daver, Naval G.
    Ohanian, Maro N.
    Brandt, Mark
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [2] Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia
    Borthakur, Gautam
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Patel, Keyur
    Ravandi, Farhad
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Daver, Naval G.
    Yilmaz, Musa
    Estrov, Zeev E.
    Ohanian, Maro N.
    Maduike, Rita
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [3] Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia.
    Borthakur, Gautam
    Cortes, Jorge E.
    O'Brien, Susan Mary
    Kadia, Tapan M.
    Estrov, Zeev
    Faderl, Stefan
    Ravandi, Farhad
    Gandhi, Varsha
    Plunkett, William
    Bass, Joyce
    Brandt, Mark
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Idarubicin, fludarabine, cytarabine and G-CSF (FLAG-Ida) for the treatment of high risk myeloid malignancies
    Parker, JE
    Cullis, JO
    Mijovic, A
    Pagliuca, A
    Mufti, GJ
    BLOOD, 1996, 88 (10) : 1803 - 1803
  • [5] Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as frontline regimen in patients with core binding factor acute myelogenous leukemia
    Borthakur, Gautam
    Cortes, Jorge E.
    Estey, Elihu E.
    Jabbour, Elias
    Faderl, Stefan
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Kadia, Tapan Mahendra
    Wang, Xuemei
    Patel, Keyur
    Luthra, Rajyalakshmi
    Koller, Charles
    Brandt, Mark
    Ravandi, Farhad
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (10) : 964 - 968
  • [6] FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies
    de la Rubia, J
    Regadera, AI
    Martín, G
    Cervera, J
    Sanz, G
    Martínez, JA
    Jarque, I
    García, I
    Andreu, R
    Moscardó, F
    Jiménez, C
    Mollá, S
    Benlloch, L
    Sanz, MA
    LEUKEMIA RESEARCH, 2002, 26 (08) : 725 - 730
  • [7] FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk acute myeloid leukemia and myelodysplastic syndromes
    Montesinos, Pau
    de la Rubia, Javier
    Orti, Guillermo
    Sanz, Jaime
    Martinez, David
    Mendoza, Ninotchka
    Scaff, Miguel
    Paciello, Mariliz
    Romero, Monica
    Martin, Guillermo
    Lorenzo, Ignacio
    Martinez, Jesus
    Algarra, Lorenzo
    Jarque, Isidro
    Perez-Sirvent, Mariluz
    Sanz, Guillermo
    Sanz, Miguel A.
    BLOOD, 2007, 110 (11) : 843A - 843A
  • [8] Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia
    Yalman, N
    Sarper, N
    Devecioglu, Ö
    Anak, S
    Eryilmaz, E
    Can, M
    Yenilmez, H
    Agaoglu, L
    Gedikoglu, G
    TURKISH JOURNAL OF PEDIATRICS, 2000, 42 (03) : 198 - 204
  • [9] Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia
    Parker, JE
    Pagliuca, A
    Mijovic, A
    Cullis, JO
    Czepulkowski, B
    Rassam, SMB
    Samartunga, IR
    Grace, R
    Gover, PA
    Mufti, GJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) : 939 - 944
  • [10] Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin
    Borthakur, Gautam
    Faderl, Stefan
    Ver-stovsek, Srdan
    Jones, Dan
    Gandhi, Varsha
    Estrov, Zeev
    O'Brien, Susan
    Ravandi, Farhad
    Bass, Joyce
    Brandt, Mark
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 812 - 812
12